PMDA explicitly permits reusing a document filed under a different application — under three conditions, one of which no publishing tool can check. What the software does about that gap is a design decision with real consequences.
You have found a stale hyperlink in a sequence you filed eighteen months ago. The correct fix is obvious. The correct place to write it is not the file you are looking at.
Promotional submissions go through the same FDA Electronic Submissions Gateway as everything else — but the account setup, the test submission, and OPDP’s own structural review are three separate lead times that teams routinely discover in the wrong order.
A grouped submission lets one promotional piece cover several applications at once. It is the biggest efficiency available in ad-promo publishing, and the easiest to get subtly wrong.
OPDP publishes the errors it sees most often in promotional eCTD submissions. Most are structural, most are silent, and several fail in ways that are not obvious from the rejection notice.
Where each piece of a Form FDA 2253 submission belongs in the eCTD — the form, the current labeling, and the promotional material itself — and why the placement is not obvious from the guidance alone.
We automated 50+ operational qualification scripts and learned that the hard part isn’t automation — it’s honesty. How to build OQ evidence a QA auditor can actually trust.
Grouped submissions let one sequence serve multiple related FDA applications. Here is how the mechanics actually work — shared files, member sequences, metadata mirroring, and cumulative views.
Where every FDA form lives in an eCTD submission, why the dynamic XFA versions break standard PDF viewers, and how form leaves behave across sequence lifecycles.
The eCTD backbone is harmonized; everything that gets submissions rejected is regional. A country-by-country guide to Module 1, DTD versions, and validation differences.
